Cartesian Therapeutics, Inc.
NGM: RNACLive Quote
📈 ZcoreAI Score
Our AI model analyzes Cartesian Therapeutics, Inc.'s price action across multiple timeframes using regression channels and statistical scoring.
Get RNAC Z-Score →About Cartesian Therapeutics, Inc.
Healthcare
Biotechnology
Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company's lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile dermatomyositis. It is also developing Descartes-15, which is in phase 1 trials, an autologous autologous B cell maturation antigen (BCMA) directed mRNA CAR-T to treat patients with multiple myeloma. The company is headquartered in Frederick, Maryland.
📊 Fundamental Analysis
Cartesian Therapeutics, Inc. demonstrates a profit margin of 0.0%, which is below the sector average, suggesting competitive pressure.
At a current price of $5.98, RNAC currently trades near the bottom of its 52-week range (4%), indicating potential value or weakness (Range: $5.60 - $15.57).
🏥 Financial Health
🔴
Profit Margin
Weak
✅
Beta (Risk)
Low Volatility
Key Financials
Market Cap
$158.52M
Trailing P/E
--
Forward P/E
-3.54
Beta (5Y)
0.56
52W High
$15.57
52W Low
$5.60
Avg Volume
178K
Day High
Day Low